Home LiteratureArticle Details
PMID: 19846533 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Journal of virology ·Vol. 84 ·No. 1 ·2010-01-00 ·Pages 163-75

Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K

Abstract

Ebolavirus (EBOV) entry into cells requires proteolytic disassembly of the viral glycoprotein, GP. This proteolytic processing, unusually extensive for an enveloped virus entry protein, is mediated by cysteine cathepsins, a family of endosomal/lysosomal proteases. Previous work has shown that cleavage of GP by cathepsin B (CatB) is specifically required to generate a critical entry intermediate. The functions of this intermediate are not well understood. We used a forward genetic strategy to investigate this CatB-dependent step. Specifically, we generated a replication-competent recombinant vesicular stomatitis virus bearing EBOV GP as its sole entry glycoprotein and used it to select viral mutants resistant to a CatB inhibitor. We obtained mutations at six amino acid positions in GP that independently confer complete resistance. All of the mutations reside at or near the GP1-GP2 intersubunit interface in the membrane-proximal base of the prefusion GP trimer. This region forms a part of the "clamp" that holds the fusion subunit GP2 in its metastable prefusion conformation. Biochemical studies suggest that most of the mutations confer CatB independence not by altering specific cleavage sites in GP but rather by inducing conformational rearrangements in the prefusion GP trimer that dramatically enhance its susceptibility to proteolysis. The remaining mutants did not show the preceding behavior, indicating the existence of multiple mechanisms for acquiring CatB independence during entry. Altogether, our findings suggest that CatB cleavage is required to facilitate the triggering of viral membrane fusion by destabilizing the prefusion conformation of EBOV GP.

MeSH Terms
Animals Cathepsin B/metabolism Chlorocebus aethiops Ebolavirus/genetics Glycoproteins/genetics Mutation Peptide Hydrolases/metabolism Protein Stability Vero Cells Viral Proteins Virus Internalization
Chemicals
Glycoproteins Viral Proteins Peptide Hydrolases Cathepsin B
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wong Anthony C
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Sandesara Rohini G
Mulherkar Nirupama
Whelan Sean P
Chandran Kartik
References (68)
68 references, click to expand
  1. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies.
    Arch Virol Suppl. 2008;20:13-360 PMID: 18637412
  2. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.
    J Virol. 2007 Jul;81(14):7702-9 PMID: 17475648
  3. An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.
    J Mol Biol. 2007 Nov 16;374(1):64-79 PMID: 17920626
  4. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.
    Science. 2005 Jun 10;308(5728):1643-5 PMID: 15831716
  5. Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle.
    J Virol. 1987 Aug;61(8):2351-61 PMID: 2885424
  6. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells.
    J Biol Chem. 2002 Jul 5;277(27):24609-17 PMID: 11986312
  7. Covalent modifications of the ebola virus glycoprotein.
    J Virol. 2002 Dec;76(24):12463-72 PMID: 12438572
  8. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.
    J Virol. 1999 Feb;73(2):1419-26 PMID: 9882347
  9. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding.
    J Virol. 2009 Apr;83(7):2883-91 PMID: 19144707
  10. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption.
    J Virol. 2002 Oct;76(19):9920-33 PMID: 12208969
  11. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.
    Mol Cell. 1998 Nov;2(5):605-16 PMID: 9844633
  12. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
    PLoS Pathog. 2008 Nov;4(11):e1000212 PMID: 19023410
  13. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L.
    Virology. 2006 Mar 15;346(2):251-7 PMID: 16460775
  14. Ebolavirus and Marburgvirus: insight the Filoviridae family.
    Mol Aspects Med. 2008 Jun;29(3):151-85 PMID: 18063023
  15. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.
    J Virol. 2003 Jan;77(2):1069-74 PMID: 12502822
  16. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones.
    Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92 PMID: 7667300
  17. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates.
    J Virol. 2007 Mar;81(6):2995-8 PMID: 17229700
  18. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.
    J Virol. 2004 Mar;78(6):2943-7 PMID: 14990712
  19. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.
    J Virol. 1999 Oct;73(10):8907-12 PMID: 10482652
  20. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.
    J Virol. 2004 May;78(10):5458-65 PMID: 15113924
  21. Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase.
    Eur J Biochem. 2000 Sep;267(17):5404-12 PMID: 10951198
  22. A system for functional analysis of Ebola virus glycoprotein.
    Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9 PMID: 9405687
  23. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities.
    Biochemistry. 2001 Mar 6;40(9):2702-11 PMID: 11258881
  24. Cathepsin B, Cathepsin H, and cathepsin L.
    Methods Enzymol. 1981;80 Pt C:535-61 PMID: 7043200
  25. Conformational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes.
    Virology. 1986 Dec;155(2):484-97 PMID: 3788061
  26. MEROPS: the peptidase database.
    Nucleic Acids Res. 2008 Jan;36(Database issue):D320-5 PMID: 17991683
  27. Influenza virus strains with a fusion threshold of pH 5.5 or lower are inhibited by amantadine. Brief report.
    Arch Virol. 1986;90(1-2):173-81 PMID: 3089198
  28. New intermediate subviral particles in the in vitro uncoating of reovirus virions by chymotrypsin.
    J Virol. 1973 Apr;11(4):552-64 PMID: 4349495
  29. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.
    J Virol Methods. 2009 Sep;160(1-2):7-13 PMID: 19433112
  30. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.
    J Biol Chem. 2006 Jun 9;281(23):15951-8 PMID: 16595665
  31. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.
    J Virol. 2007 Oct;81(19):10567-74 PMID: 17652384
  32. Processing of the Ebola virus glycoprotein by the proprotein convertase furin.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7 PMID: 9576958
  33. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.
    Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6 PMID: 19321428
  34. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    J Virol. 2009 Jul;83(14):7296-304 PMID: 19386702
  35. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry.
    J Virol. 2006 Jun;80(12):5768-76 PMID: 16731916
  36. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.
    Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219 PMID: 18568847
  37. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide.
    J Virol. 2009 Aug;83(15):7411-21 PMID: 19439480
  38. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.
    Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81 PMID: 16081529
  39. Functional importance of the coiled-coil of the Ebola virus glycoprotein.
    J Virol. 2000 Nov;74(21):10194-201 PMID: 11024148
  40. Influenza hemagglutinin is spring-loaded by a metastable native conformation.
    Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14306-13 PMID: 9405608
  41. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.
    J Virol. 2006 Apr;80(8):4174-8 PMID: 16571833
  42. Filoviruses: recent advances and future challenges.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S129-30 PMID: 17940939
  43. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Nature. 2008 Jul 10;454(7201):177-82 PMID: 18615077
  44. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.
    J Virol. 1998 Apr;72(4):3155-60 PMID: 9525641
  45. Development of a new vaccine for the prevention of Lassa fever.
    PLoS Med. 2005 Jun;2(6):e183 PMID: 15971954
  46. The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyldipeptidase mechanism.
    Biochem J. 1978 Jun 1;171(3):759-65 PMID: 666735
  47. Viral membrane fusion.
    Nat Struct Mol Biol. 2008 Jul;15(7):690-8 PMID: 18596815
  48. Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses.
    Cell. 1996 May 17;85(4):477-8 PMID: 8653783
  49. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2662-7 PMID: 10077567
  50. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.
    J Biol Chem. 2006 Feb 10;281(6):3198-203 PMID: 16339146
  51. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
    Virology. 2005 Sep 30;340(2):174-82 PMID: 16043204
  52. Early steps in reovirus infection are associated with dramatic changes in supramolecular structure and protein conformation: analysis of virions and subviral particles by cryoelectron microscopy and image reconstruction.
    J Cell Biol. 1993 Sep;122(5):1023-41 PMID: 8394844
  53. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
    Virology. 2003 Jan 5;305(1):115-23 PMID: 12504546
  54. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.
    Cell Microbiol. 2010 Feb;12(2):148-57 PMID: 19775255
  55. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.
    J Virol. 2007 Dec;81(24):13378-84 PMID: 17928356
  56. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain.
    Virology. 2007 Aug 1;364(2):342-54 PMID: 17434557
  57. Generation of biologically contained Ebola viruses.
    Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1129-33 PMID: 18212124
  58. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
    Nature. 1992 Nov 26;360(6402):358-61 PMID: 1360148
  59. Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.
    J Virol. 2006 Jan;80(1):353-9 PMID: 16352560
  60. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.
    J Virol. 2006 Oct;80(19):9659-66 PMID: 16973570
  61. A positive-feedback mechanism promotes reovirus particle conversion to the intermediate associated with membrane penetration.
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10571-6 PMID: 18653761
  62. A carboxy-terminal fragment of protein mu 1/mu 1C is present in infectious subvirion particles of mammalian reoviruses and is proposed to have a role in penetration.
    J Virol. 1992 Nov;66(11):6408-18 PMID: 1328674
  63. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide.
    J Virol. 2008 Sep;82(17):8887-90 PMID: 18562523
  64. Comprehensive analysis of ebola virus GP1 in viral entry.
    J Virol. 2005 Apr;79(8):4793-805 PMID: 15795265
  65. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
    Nat Med. 2005 Jul;11(7):786-90 PMID: 15937495
  66. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities.
    J Biol Chem. 2006 May 5;281(18):12824-32 PMID: 16520377
  67. Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis.
    J Virol. 2009 Nov;83(21):11133-41 PMID: 19706706
  68. CellProfiler: image analysis software for identifying and quantifying cell phenotypes.
    Genome Biol. 2006;7(10):R100 PMID: 17076895
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2010-01-00
Pages
163-75
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2798398
Subset
IM
Grants
NIAID NIH HHS · K22 AI074908 · United States
NIAID NIH HHS · T32 AI070117 · United States
NIGMS NIH HHS · T32 GM007288 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com